A study on advanced melanoma patients demonstrated increase in tumor-infiltrating lymphocytes in early on-treatment biopsies of patients benefiting from the therapy, but no significant change in the number of CD8+ T cells [38]. This evidence concerns the gene CD8A and neoplasm.